A61K 9 - Medicinal preparations characterised by special physical form

Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
12/2002
12/03/2002	US6488933 Preparations for the treatment of T cell mediated diseases
12/03/2002	US6488929 Candida albicans phosphomannan complex as a vaccine
12/03/2002	US6488928 Product for topical application containing a lipase and a hydroxy acid precursor
12/03/2002	US6488923 Inhibits elastase; inhibits inflammations; used for the preparation of a vasoregulatory and or collagen activating medicament and to treat gingivitis.
12/03/2002	US6488615 Permanent magnet keeper-shield assembly
12/03/2002	US6488164 Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
12/03/2002	CA2283915C The use of alkyl hydrogen fumarates for treating psoriasis, psoriatic arthritis, neurodermatitis and enteritis regionalis crohn
12/03/2002	CA2259343C Novel radiopharmaceutical compositions and matrices and uses thereof
12/03/2002	CA2253061C A novel anti-allergy anti-inflammatory composition
12/03/2002	CA2204475C Pharmaceutical composition containing stabilized lipophilic matrices for the controlled release of active substances
12/03/2002	CA2126103C Transfection of lung via aerosolized transgene delivery
12/03/2002	CA2116478C Prolonged delivery of peptides
12/03/2002	CA2095789C Transdermal administration system for estradiol
12/03/2002	CA2039773C Cosmetic composition or aqueous dermo-pharmaceutical containing a suspension of hydrophile lipidic substance hydrated
12/03/2002	CA2021580C Polysiloxane-grafted copolymer topical binder composition with novel fluorochemical comonomer and method of coating therewith
11/2002
11/30/2002	CA2389560A1 Cosmetic and/or dermatological and/or pharmaceutical compound for topical application, containing at least one 3 beta-hydroxysteroid dehydrogenase enzyme inhibitor
11/30/2002	CA2388169A1 Phospholipid composition and use of same
11/30/2002	CA2387821A1 Azalide antibiotic compositions
11/28/2002	WO2002095391A1 Methods and formulations for increasing the affinity of a1 adenosine receptor ligands for the a1 adenosine receptor
11/28/2002	WO2002095341A1 Fluid delivery device having a water generating electrochemical/chemical pump and associated method
11/28/2002	WO2002095027A2 Immunostimulatory oligodeoxynucleic molecules
11/28/2002	WO2002094875A1 HAb18G/CD147, IT'S AGONIST AND APPLICATION
11/28/2002	WO2002094845A2 Method for stabilising of nucleic acids
11/28/2002	WO2002094774A2 Oxcarbazepine dosage forms
11/28/2002	WO2002094369A1 Device for applying substances
11/28/2002	WO2002094368A1 Transdermal drug delivery devices having coated microprotrusions
11/28/2002	WO2002094342A2 Compositions for protein delivery via the pulmonary route
11/28/2002	WO2002094324A1 Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
11/28/2002	WO2002094323A1 Weight reduction or weight controlling composition
11/28/2002	WO2002094321A1 Compositions for promoting healing of bone fracture
11/28/2002	WO2002094320A1 Therapeutic compositions for repairing chondropathy
11/28/2002	WO2002094316A2 Method of preparing aluminium-hydroxide gel
11/28/2002	WO2002094294A1 A method of implanting heavy metal such as nobel metal, e.g. gold, and metal for use in implantation
11/28/2002	WO2002094288A1 Veterinary compositions comprising avermectin-oxime derivatives and praziquantel
11/28/2002	WO2002094285A1 Single-daily-dose antidiabetic oral pharmaceutical form comprising a biguanide and at least another active principle
11/28/2002	WO2002094283A2 Use of phospholipids in the treatment of degenerative lung disease such as copd or cystic fibrosis and to enhance delivery of drugs
11/28/2002	WO2002094282A2 Compositions with methylprednisolone derivatives having therapeutic effect
11/28/2002	WO2002094278A1 Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
11/28/2002	WO2002094276A1 Pharmaceutical composition for use in hormone replacement therapy
11/28/2002	WO2002094275A1 Use of estrogen compounds to increase libido in women
11/28/2002	WO2002094273A2 Combination of an adenosine a2a-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways
11/28/2002	WO2002094269A1 Liposomally encapsulated hydrophobic active ingredients with a high active ingredient content ⊃ 50 % and method for the production of pharmaceutical preparations containing liposomally encapsulated hydrophobic active ingredients
11/28/2002	WO2002094258A1 Improved dosage form of n-acetyl cysteine
11/28/2002	WO2002094257A1 Analgesic/antiinflammatory patches for topical use
11/28/2002	WO2002094254A2 Abuse resistant pharmaceutical composition containing capsaicin
11/28/2002	WO2002094248A2 Composition and use of substances for stabilising amino acids containing sulphur and/or for inhibiting the continuous formation of amino acids containing sulphur in a blood sample
11/28/2002	WO2002094246A2 Delivery of nonsteroidal antiinflammatory drugs through an inhalation route
11/28/2002	WO2002094245A1 Delivery of antihistamines through an inhalation route
11/28/2002	WO2002094244A2 Delivery of benzodiazepines through an inhalation route
11/28/2002	WO2002094243A1 Delivery of sumatriptan, frovatriptan or naratriptan through an inhalation route
11/28/2002	WO2002094242A1 Delivery of rizatriptan or zolmitriptan through an inhalation route
11/28/2002	WO2002094241A1 Delivery of compounds for the treatment of migraine through an inhalation route
11/28/2002	WO2002094240A1 Delivery of physiologically active compounds through an inhalation route
11/28/2002	WO2002094239A1 Delivery of diphenhydramine through an inhalation route
11/28/2002	WO2002094238A1 Delivery of anti-migraine compounds through an inhalation route
11/28/2002	WO2002094237A1 Delivery of beta-blockers through an inhalation route
11/28/2002	WO2002094236A1 Delivery of antipsychotics through an inhalation route
11/28/2002	WO2002094235A1 Delivery of compounds for the treatment of parkinsons through an inhalation route
11/28/2002	WO2002094234A1 Delivery of opioids through an inhalation route
11/28/2002	WO2002094233A1 Delivery of antiemetics through an inhalation route
11/28/2002	WO2002094232A1 Delivery of antidepressants through an inhalation route
11/28/2002	WO2002094231A1 Delivery of analgesics through an inhalation route
11/28/2002	WO2002094230A1 Delivery of sedative-hypnotics trough an inhalation route
11/28/2002	WO2002094229A1 Delivery of muscle relaxants through an inhalation route
11/28/2002	WO2002094228A1 Prevention and treatment of allergies by helminthic regulation of ige
11/28/2002	WO2002094227A1 Controlled release drug delivery device
11/28/2002	WO2002094226A1 Homogenised product for implants and microparticles
11/28/2002	WO2002094225A1 Granular preparations of gaboxadol
11/28/2002	WO2002094224A1 Biocompatible compositions as carriers or excipients for pharmaceutical and nutraceutical formulations and for good protection
11/28/2002	WO2002094223A2 Formulation containing halofantrine hydrochloride
11/28/2002	WO2002094222A2 Method for the production of nanodispersions
11/28/2002	WO2002094221A1 Emulsion and dispersion formulations and method
11/28/2002	WO2002094220A1 Liquid pharmaceutical composition
11/28/2002	WO2002094219A2 Delivery of erectile dysfunction drugs through an inhalation route
11/28/2002	WO2002094218A2 Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
11/28/2002	WO2002094217A1 Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
11/28/2002	WO2002094216A2 Delivery of stimulants through an inhalation route
11/28/2002	WO2002094215A2 Nanoparticulate compositions comprising a drug and copolymers of vinyl pyrrolidone and vimyl acetate as surface stabilizers
11/28/2002	WO2002094200A2 Pulmonary administration of chemically modified insulin
11/28/2002	WO2002094189A2 Compositions and methods for treating or preventing convulsions or seizures
11/28/2002	WO2002094178A2 Treatment of renal fibrosis
11/28/2002	WO2002094174A2 Container and method for dispensing transdermal dosage forms
11/28/2002	WO2002094172A2 Compartmentalized dosage form
11/28/2002	WO2002094002A2 Cultivated agarwood
11/28/2002	WO2002080887A3 Timed pulse release composition
11/28/2002	WO2002080859A3 Inhalation drug combinations
11/28/2002	WO2002080648A3 Mucosal boosting following parenteral priming
11/28/2002	WO2002078675A3 Particles for inhalation having sustained release properties
11/28/2002	WO2002078616A3 Methods for increasing serotonin levels by administering (-)-hydroxycitric acid
11/28/2002	WO2002078566A3 Prosthetic foot with tunable performance
11/28/2002	WO2002072080A3 Paracetamol solutions which are stable in storage and ready for infusion
11/28/2002	WO2002064557A9 New crystal forms of oxcarbazepine and processes for their preparation
11/28/2002	WO2002062394A3 Vegetable polymer-based composition that immobilises active agents
11/28/2002	WO2002011702A3 Hydrogel-driven drug dosage form
11/28/2002	WO2001089542A3 Composition for improving the cell protection comprising a lipophilic antioxidant and a hydrophilic antioxidant
11/28/2002	WO2001087227A3 Drug containing polymeric micelles
11/28/2002	WO2001082897A3 Liposome drug delivery
11/28/2002	WO2001049277A3 Immune response modulation
11/28/2002	WO2001035942A9 Analgesic compositions containing buprenorphine
11/28/2002	US20020177839 Microprojection array having a beneficial agent containing coating

1 ... 2206 2207 2208 2209 2210 2211 2212 2213 2214 2215 2216 2217 2218 2219 2220 2221 2222 2223 2224 2225 2226 ... 2991